SpaceX Launches Inaugural Bond Offering Seeking $20 Billion Post-IPO
Money

SpaceX Launches Inaugural Bond Offering Seeking $20 Billion Post-IPO

authorBy Dave Ramsey
DateJun 22, 2026
Read Time3 min

Following a landmark initial public offering that positioned its market capitalization beyond the $2 trillion threshold, SpaceX has initiated its first venture into the public bond market. The company seeks to secure $20 billion through this offering, with plans to allocate these funds towards settling existing bridge loans, covering related operational costs, and bolstering its general corporate finances, including substantial investments in artificial intelligence infrastructure. This strategic financial maneuver occurs amidst a recent dip in SpaceX's stock performance.

SpaceX's Strategic Debt Issuance and Future Vision

On Monday, June 22, 2026, Space Exploration Technologies Corp. publicly revealed its intention to issue senior unsecured notes, marking its inaugural entry into the public bond market. This announcement came shortly after the successful conclusion of the largest initial public offering ever recorded, which valued the company at over $2 trillion following its June 12 pricing at $135 per share. The bond offering aims to raise a minimum of $20 billion, with maturities ranging from five to thirty years.

According to its SEC filings, SpaceX plans to utilize the net proceeds primarily to fully repay outstanding amounts under its existing bridge loan facility. Any remaining capital will be directed towards general corporate purposes, notably a significant expansion into AI infrastructure. This includes the development of data centers and related technologies, with agreements totaling approximately $75 billion with industry giants Google and Anthropic for computing capacity. Furthermore, the company is actively exploring the ambitious prospect of establishing data centers in space, as reported by CNBC.

The notes will be offered to qualified institutional buyers under Rule 144A and to non-U.S. entities under Regulation S, emphasizing their placement within sophisticated investment circles. The bonds are not registered under the Securities Act and cannot be sold in the United States without proper registration or an applicable exemption.

Leading financial institutions, including Bank of America, Citigroup, Goldman Sachs, JPMorgan Chase, and Morgan Stanley, which were instrumental in the initial bridge financing, are now facilitating investor calls for this bond sale. This bridge loan currently constitutes the majority of SpaceX's approximately $29.1 billion in long-term debt, as noted by Bloomberg.

Prior to this offering, SpaceX secured investment-grade ratings from all three major rating agencies: Moody's Ratings assigned a Baa1, Fitch Ratings issued a BBB+, and S&P Global Ratings provided a BBB. As of June 19, 2026, the company reported a robust financial position with approximately $100.8 billion in cash and cash equivalents.

Despite these positive developments, SpaceX's stock experienced a decline of about 5% on Monday, continuing a losing streak from the previous week. This downturn was partly attributed to MSCI's assignment of its lowest possible ESG rating, CCC, citing concerns over the company's management of environmental, social, and governance risks.

The bond sale signifies a strategic shift in SpaceX's financing approach. During the IPO roadshow, executives Bret Johnsen and Gwynne Shotwell indicated to prospective shareholders that future capital requirements would be met through debt issuance rather than additional equity sales, portraying the IPO as a singular equity event.

SpaceX's bold foray into the bond market, particularly following a monumental IPO, illustrates a sophisticated financial strategy aimed at fueling ambitious expansion, especially in cutting-edge areas like AI. This move also highlights the complex balance between rapid innovation, significant capital demands, and market perception, as evidenced by the recent stock fluctuations and ESG rating challenges. It underscores the evolving landscape where even leading-edge companies must navigate traditional financial instruments and growing scrutiny over corporate governance and sustainability.

More Articles
Money
Allient's Strategic Pivot: Growth in Robotics, Defense, and Automation
Allient Inc. (ALNT), despite being considered overvalued by some short-sellers, has garnered an 'Overweight' rating and an increased price target from JPMorgan. The firm highlights Allient's successful transition into a vertically integrated engineering platform, combining motion, control, and power technologies. This strategic evolution positions the company strongly in high-growth sectors like defense, industrial automation, and humanoid robotics, with expectations of mid-single-digit revenue growth and margin expansion.
By Dave RamseyJun 22, 2026
Money
Lemonade Expands Renters Insurance to Montana, Price Target Raised
Lemonade, Inc. (LMND) has expanded its renters insurance product to Montana, continuing its growth in the US market. This move aligns with the company's aim to simplify insurance through digital solutions. Following this expansion, TD Cowen increased its price target for LMND to $55 from $33, while maintaining a 'Hold' rating. Lemonade, established in 2015, leverages AI and behavioral economics to provide various insurance policies, including specialized pet health coverage.
By Ramit SethiJun 22, 2026
Money
New Clinical Data Fuels Optimism for Teva's Austedo and Biosimilar Expansion
Teva Pharmaceutical Industries Limited (TEVA) has reported encouraging new clinical data for its tardive dyskinesia treatment, Austedo, showcasing significant improvements in patients' involuntary movements and daily activities. Simultaneously, the company has expanded its biosimilar portfolio with the European launch of Ahzantive, a biosimilar version of Eylea, further solidifying its presence in the ophthalmology market and diversifying its revenue streams. These developments point to a promising outlook for the global pharmaceutical giant.
By Mr. Money MustacheJun 22, 2026
Money
Gilead's HIV Prevention Breakthrough and Global Health Efforts
Gilead Sciences, Inc. is advancing its HIV prevention portfolio with a new once-weekly oral PrEP treatment, Yeztugo, recently accepted by the FDA for review with a target action date of February 2, 2027. Concurrently, Gilead has donated over 2,000 vials of its antiviral remdesivir to Uganda to combat the Ebola Bundibugyo virus outbreak, demonstrating its commitment to addressing global health crises.
By Bola SokunbiJun 22, 2026
Money
Novo Nordisk: A Leading Player in Longevity and Anti-Aging Market
Novo Nordisk A/S, a prominent global healthcare firm, is recognized as a top longevity and anti-aging stock. With a short interest of 0.51%, the company received an upgraded price target and a 'Buy' rating from Berenberg analyst Kerry Holford on June 17. The UK's Medicines and Healthcare products Regulatory Agency recently approved their oral GLP-1 therapy, Wegovy, for weight management, expanding their obesity treatment options with a non-injectable alternative.
By Scott PapeJun 22, 2026